Possibly the introduction of GnRH trigger for final oocyte maturation, known to decrease the risk for hyperstimulation, and the increased use of letrozole during COH of breast cancer patients have decreased potential complication risks and led to fertility doctors feeling safer to use larger doses of gonadotropin, affecting our results. This evidence concerns the gene GNRH1 and breast cancer.